<DOC>
	<DOCNO>NCT01573338</DOCNO>
	<brief_summary>This first study BAY1000394 give combination chemotherapy : cisplatin / etoposide carboplatin / etoposide . Patients small cell lung cancer treat . Every patient receive drug treatment , placebo group . Different group patient receive different dosage BAY1000394 determine safety maximum tolerate dose ( MTD ) BAY1000394 combination chemotherapy . The dose chemotherapy standard dose usually administer change . The study also assess drug metabolize body change tumor size . BAY1000394 give per mouth , twice day three day every week . Treatment stop tumor continue grow , side effect occur patient tolerate patient decide exit treatment .</brief_summary>
	<brief_title>Clinical Study Evaluate Maximum Tolerated Dose BAY1000394 When Given Together With Chemotherapy Effectiveness This Combination Treatment Shrinking Specific Type Lung Tumors ( Small Cell Lung Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Male female subject age &gt; /=18 year Histologically cytologically confirm , extensive disease SCLC At least 1 solid tumor lesion measurable computer tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord RECIST 1.1 . Subjects nonmeasurable disease accord RECIST 1.1 include Phase Ib part study Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Serum sodium &gt; /=130 mmol/L Prior systemic anticancer therapy Prior radiotherapy ( local palliative radiotherapy permit ) History cardiac disease : congestive heart failure &gt; NYHA Class II , unstable angina ( anginal symptom rest ) , episodes angina history myocardial infarction , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) , previous venous arterial thrombotic event , pulmonary embolism Moderate severe hepatic impairment , ie ChildPugh class B C Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cyclin dependent kinase</keyword>
	<keyword>Drug therapy , combination</keyword>
	<keyword>Small cell lung carcinoma</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Carboplatin</keyword>
</DOC>